Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Physician lesson

Bone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jaw

Zoledronic acid and denosumab: dose, interval, dental care and prevention

Updated: 28 October 20261 min read4 references

Key points

  • Bone metastases from breast cancer: zoledronic acid 4 mg every 3 to 4 weeks or every 12 weeks, or denosumab 120 mg every 4 weeks [1].
  • Before starting: a dental examination and completion of invasive dental treatment [2].
  • Calcium and vitamin D alongside, especially with denosumab (hypocalcaemia).
  • Adjuvant bisphosphonates in postmenopausal women reduced bone recurrence and breast cancer deaths [3].

Bone metastases

Bone-modifying agents reduce skeletal-related events (fractures, spinal cord compression, need for radiotherapy or surgery) [1]. Zoledronic acid every 12 weeks is an acceptable alternative to every 4 weeks [1]. Adjust zoledronic acid for creatinine clearance and check creatinine before each dose. After stopping denosumab, rapid loss of bone density and vertebral fractures can occur; if it is stopped, consider a bisphosphonate.

Osteonecrosis of the jaw

  • Before starting: a dental examination; complete tooth extractions and invasive surgery before starting (preferably 14 to 21 days before) [2].
  • During treatment: oral hygiene and regular dental visits; avoid unnecessary dental surgery [2].
  • Refer pain, swelling or exposed bone in the mouth to an oral surgeon straight away [2].

Adjuvant bisphosphonates in breast cancer

In the EBCTCG meta-analysis, adjuvant bisphosphonates in postmenopausal women reduced bone recurrence by about 28% and breast cancer deaths by about 18%; there was no benefit in premenopausal women [3]. The ASCO and CCO guideline suggests them for postmenopausal women (natural or treatment-induced) who are candidates for adjuvant chemotherapy or other adjuvant treatment: zoledronic acid 4 mg every 6 months for 3 to 5 years, or oral clodronate [4].

Related cancer types

Breast cancerProstate cancerMultiple myeloma

Treatment regimens (physicians)

AC followed by paclitaxel (dose-dense and weekly)TC regimen (docetaxel and cyclophosphamide): dose and scheduleTCHP regimen: dose and schedule in HER2-positive breast cancerWeekly paclitaxel with trastuzumab (APT regimen)KEYNOTE-522 regimen: pembrolizumab and chemotherapy in triple-negative breast cancerTrastuzumab emtansine (T-DM1, Kadcyla): dose and scheduleTrastuzumab deruxtecan (T-DXd, Enhertu): dose and monitoringAdjuvant capecitabine after neoadjuvant treatment (CREATE-X)Sacituzumab govitecan (Trodelvy)Pembrolizumab with chemotherapy in metastatic triple-negative breast cancer (KEYNOTE-355)Docetaxel in metastatic prostate cancerDarolutamide with docetaxel and hormone therapy (ARASENS)

Physician tools and lessons

Cumulative Anthracycline Dose and Doxorubicin EquivalentsHCT-CI Comorbidity Index Before Stem Cell TransplantationMyeloma Staging Calculator: ISS, R-ISS and R2-ISSLocalised Prostate Cancer Risk Group CalculatorIndications for haematopoietic stem cell transplantation, donor selection and conditioningGraft-versus-host disease (GVHD): prophylaxis, grading and treatment10 cheap steps that save patients' livesGermline genetic testing in cancer: who, and which genes?Management of brain metastasesFertility preservation before cancer treatment

References

4 references
Show all references, 1 with a study cardClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline UpdateVan Poznak C, Somerfield MR, Barlow WE, et al · J Clin Oncol · 2017;35:3978-3986
    DOIPubMed Back to text: 1 2 3
  2. 2
    Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice GuidelineYarom N, Shapiro CL, Peterson DE, et al · J Clin Oncol · 2019;37:2270-2290
    DOIPubMed Back to text: 1 2 3 4
  3. 3
    Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trialsLancet · 2015;386:1353-1361
    Study cardDOIPubMed Back to text: 1 2
  4. 4
    Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice GuidelineDhesy-Thind S, Fletcher GG, Blanchette PS, et al · J Clin Oncol · 2017;35:2062-2081
    DOIPubMed Back to text

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/learn/bone-health-bone-metastases/

Related pages

27 October 2026 DPYD, UGT1A1 and TPMT/NUDT15 testing before chemotherapy A guide to DPYD testing before fluorouracil and capecitabine, UGT1A1 before irinotecan and TPMT/NUDT15 before mercaptopurine, with genotype-guided dosing. 27 October 2026 Hepatitis B and chemotherapy: screening and prevention of reactivation A guide to hepatitis B screening before chemotherapy, rituximab and transplant, reactivation risk groups, and prophylaxis with entecavir or tenofovir. 27 October 2026 Febrile neutropenia: assessment, empirical antibiotics and outpatient treatment A complete lesson on managing febrile neutropenia in cancer patients: definition, first-hour assessment, choice of empirical antibiotic, indications for vancomycin and antifungals, outpatient treatment and duration of treatment.